Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study
- PMID: 22386743
- DOI: 10.1016/j.ijantimicag.2012.01.002
Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study
Abstract
Resistance rates amongst Gram-negative pathogens are increasing in the Asia-Pacific region. The Comparative Activity of Carbapenem Testing (COMPACT) II study surveyed the carbapenem susceptibility and minimum inhibitory concentrations (MICs) of doripenem, imipenem and meropenem against 1260 major Gram-negative pathogens isolated from hospitalised patients at 20 centres in five Asia-Pacific countries (New Zealand, the Philippines, Singapore, Thailand and Vietnam) during 2010. Pseudomonas aeruginosa (n=625), Enterobacteriaceae (n=500), and other Gram-negative pathogens including Acinetobacter baumannii (n=135) were collected from patients with bloodstream infection (32.2%), nosocomial pneumonia including ventilator-associated pneumonia (58.1%), and complicated intra-abdominal infection (9.7%), with 36.7% being isolated from patients in an Intensive Care Unit. As high as 29.8% of P. aeruginosa and 73.0% of A. baumannii isolates were not susceptible to at least a carbapenem, whereas the majority of Enterobacteriaceae (97.2%) were susceptible to all carbapenems. Respective MIC(50)/MIC(90) values (MICs for 50% and 90% of the organisms, respectively) of doripenem, imipenem and meropenem were: 0.38/8, 1.5/32 and 0.38/16 mg/L for P. aeruginosa; 0.023/0.094, 0.25/0.5 and 0.032/0.094 mg/L for Enterobacteriaceae; and 32/64, 32/128 and 32/64 mg/L for A. baumannii. Doripenem and meropenem had comparable activity against P. aeruginosa, both being more active than imipenem. All carbapenems were highly potent against Enterobacteriaceae, although imipenem demonstrated higher MIC values than doripenem and meropenem. The three carbapenems showed less activity against A. baumannii. The high prevalence of carbapenem resistance amongst important nosocomial pathogens (P. aeruginosa and A. baumannii) warrants rigorous infection control measures and appropriate antimicrobial use in the Asia-Pacific region.
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Similar articles
-
In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study.Int J Antimicrob Agents. 2010 Dec;36(6):501-6. doi: 10.1016/j.ijantimicag.2010.08.002. Int J Antimicrob Agents. 2010. PMID: 20869212
-
Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.Int J Antimicrob Agents. 2012 Mar;39(3):255-8. doi: 10.1016/j.ijantimicag.2011.10.015. Epub 2012 Jan 9. Int J Antimicrob Agents. 2012. PMID: 22230334
-
Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.Int J Antimicrob Agents. 2013 Jan;41(1):47-51. doi: 10.1016/j.ijantimicag.2012.09.007. Epub 2012 Nov 3. Int J Antimicrob Agents. 2013. PMID: 23127484
-
Doripenem: position in clinical practice.Expert Rev Anti Infect Ther. 2009 Jun;7(5):507-14. doi: 10.1586/eri.09.37. Expert Rev Anti Infect Ther. 2009. PMID: 19485791 Review.
-
In vitro activity studies of doripenem and two other carbapenems tested against Pseudomonas aeruginosa and other non-fermentative bacilli.J Chemother. 2011 Dec;23(6):335-40. doi: 10.1179/joc.2011.23.6.335. J Chemother. 2011. PMID: 22233816 Review.
Cited by
-
Epidemiology and Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa.Infect Chemother. 2015 Jun;47(2):81-97. doi: 10.3947/ic.2015.47.2.81. Epub 2015 Jun 30. Infect Chemother. 2015. PMID: 26157586 Free PMC article. Review.
-
Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?Crit Care. 2015 Jan 30;19(1):28. doi: 10.1186/s13054-015-0750-y. Crit Care. 2015. PMID: 25632974 Free PMC article.
-
Antibiotic susceptibility and molecular epidemiology of Acinetobacter calcoaceticus-baumannii complex strains isolated from a referral hospital in northern Vietnam.J Glob Antimicrob Resist. 2014 Dec;2(4):318-321. doi: 10.1016/j.jgar.2014.05.003. J Glob Antimicrob Resist. 2014. PMID: 25540720 Free PMC article.
-
Risk Factors and Clinical Outcomes for Patients With Acinetobacter baumannii Bacteremia.Medicine (Baltimore). 2016 Mar;95(9):e2943. doi: 10.1097/MD.0000000000002943. Medicine (Baltimore). 2016. PMID: 26945403 Free PMC article.
-
Risk factors for progression to bacteremia among patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia in the Intensive Care Unit.Eur J Clin Microbiol Infect Dis. 2023 Nov;42(11):1337-1346. doi: 10.1007/s10096-023-04668-9. Epub 2023 Sep 28. Eur J Clin Microbiol Infect Dis. 2023. PMID: 37768395 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials